Amersham Pharmacia Biotech, Inc. v. Perkin-Elmer Corp.

190 F.R.D. 644, 2000 WL 133749
CourtDistrict Court, N.D. California
DecidedJanuary 31, 2000
DocketNo. C-97-04203 CRB/EAI
StatusPublished
Cited by7 cases

This text of 190 F.R.D. 644 (Amersham Pharmacia Biotech, Inc. v. Perkin-Elmer Corp.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Amersham Pharmacia Biotech, Inc. v. Perkin-Elmer Corp., 190 F.R.D. 644, 2000 WL 133749 (N.D. Cal. 2000).

Opinion

ORDER GRANTING MOTION TO AMEND CM L.R. 16-9(b) RESPONSE CHART

INFANTE, Chief United States Magistrate Judge.

I. INTRODUCTION

On December 20, 1999, The Perkin-Elmer Corporation (“Perkin-Elmer”) moved, pursuant to Civil L.R. 16 — 6(d) and 16-9(c), for leave to amend its Civil L.R. 16 — 9(b) Response Chart (“Response Chart”) to add Japanese Patent Publication No. 5060698A, citing “excusable subsequent discovery” of this additional prior art reference (“the Motion”). In support of the Motion, Perkin-Elmer submitted the Declaration of Edward R. Reines (“Reines Deck”), with exhibits, and the Declaration of Michael W. Hunkapiller (“Hunka-piller Deck”). With its opposition to Perkin-Elmer’s Motion, Amersham Pharmacia Bio-tech, Inc. (“Amersham”) submitted a declaration from Jeffrey W. Guise (“the Guise Deck”), with exhibits. Having reviewed and considered all of the above, the Court GRANTS the Motion, for the reasons set forth below.

II. BACKGROUND

In November 1997 Amersham sued Per-kin-Elmer for infringement of U.S. Patent No. 5,688,648 (“the ’648 patent”). On September 17, 1998, after receiving from Am-ersham its Civil L.R. 16-9(a) Claim Chart, Perkin-Elmer served its Civil L.R. 16 — 9(b) Response Chart identifying those prior art references which Perkin-Elmer contends anticipate the claims of the ’648 patent or render them obvious. The parties filed a joint claim construction statement for the ’648 patent, as required by Civil L.R. 16 — 11(b), in November 1998. In December 1998 the action was reassigned from Judge Hendersen to Judge Breyer. On January 15, 1998, Judge Breyer granted Perkin-Elmer’s motion to stay the case and relate it to other pending litigation.1 Reines Deck, Ex. A.

Perkin-Elmer’s counsel testifies that Per-kin-Elmer initiated its search for prior art references to the ’648 patent well before serving the Response Chart on September 17, 1998. Reines Deck, 112. Perkin-Elmer retained specialist Global Prior Art to perform a worldwide search and, in addition, counsel also conducted searches. Id. Both the Global Art and counsel’s searches included, but were not limited to, patents, patent applications, and articles relevant to the claims of the ’648 patent, but neither search located Japanese Patent Publication No. 5060698A. Id. On December 4, 1998, a newly hired search firm specializing in Japanese prior art searches identified Japanese Patent Publication No. 5060698A, an unexamined application, as potential prior art to the ’648 patent. Reines Deck, H 2. Perkin-Elmer obtained an English translation of the document about December 14,1998. Id.

On February 2, 1999, Perkin-Elmer’s counsel produced Japanese Patent Publication No. 5060698A to Amersham’s counsel in a closely related case, Amersham Pharmacia Biotech, Inc. v. Celera Genomics Corporation, Civil Action No. 98-591-RRM ^Delaware), filed in October 1998.2 Reines Deck, 113. On July 12,1999, this Court vacated the stay and held a case management conference, during which Perkin-Elmer raised the proposed amendment to its Response Chart. Reines Deck, 114. Shortly thereafter, Per-[646]*646kin-Elmer produced the Japanese document in this action, Reines Deck, Ex. C, and asked Amersham to stipulate to the amendment. See Reines Deck, Ex. D. Amersham’s response (July 30) was to request an English translation and ask why the Japanese reference was not included in the Response Chart. Reines Deck, Ex. E. On August 5, Perkin-Elmer provided Amersham with the English translation, explaining that the Japanese document was not located until December 1998. Reines Deck, Ex. G. Perkin-Elmer raised the proposed amendment again at the August 9 case management conference. Reines Deck, If 4; Ex. F, H 12(a).

The parties haggled over this matter from at least the July 12, 1999 case management conference until November 15, 1999, see Reines Deck, Ex. D-P, when Amersham finally refused to stipulate to the amendment, ostensibly because the reference is “merely cumulative of the other references already of record[.]” Reines Deck, Ex. P. On November 18, the Court authorized the instant Motion, which Perkin-Elmer filed on December 20.3

During October and November 1999 the parties filed their briefs on the claim construction, and the Court conducted the Markmcm hearing on December 10, 1999. Thereafter, the parties filed post-hearing briefs on January 10, 2000. The Court presently has claim construction under submission. As yet the Court has not set a fact or expert discovery cut-off, or a trial date, in this action.

III. LEGAL STANDARD

The Civil Local Rules of this District establish procedures which expand the initial disclosure requirements of Rule 26(a), F.R.Civ.P., in patent litigation. Civil L.R. 16-6 provides:

Disclosures and Pretrial Proceedings in Patent Cases.
(a) Scope. In addition to complying with Civil L.R. 16-5 and F.R.Civ.P. 26, in all civil actions filed in this court which include a claim of patent infringement, or which seek a declaratory judgment that a patent is not infringed or is invalid, the parties shall also comply with the disclosure requirements and procedures set forth in Civil L.R. 16-6 through 16-11. * * * * * *
(d) Duty to Supplement Disclosures. Unless otherwise ordered by the court, disclosures or charts governed by these are subject to the duty of supplementation of F.R.Civ.P. 26(e).

Civil L.R. 16-7, Initial Disclosure of Asserted Claims and Prior Art in Patent Cases, requires a party, within 45 days of filing a pleading asserting a patent infringement claim, to make an “Initial Disclosure of Asserted Claims” and produce specified documents to the opposing party. Civil L.R. 16-7(a)-(c). No later than 55 days after service of the “Initial Disclosure of Asserted Claims,” each opposing party must make an “Initial Disclosure of Prior Art” and an accompanying document production. Civil L.R. 16 — 7(d)—(f). Civil L.R. 16-8 addresses initial disclosures in patent cases for declaratory judgment.

Subsequent to making the initial disclosures, Civil L.R. 16-9(a) requires the party claiming infringement to serve a “claim chart.” The claim chart must identify each claim of any patent in suit which is alleged to be infringed, and the infringing instrumentality, and state whether the infringement is claimed to be literal or under the doctrine of equivalents, where each element of each claim is found within an infringing instrumentality, and identify how the accusing party’s own product embodies a particular claim. Civil L.R. 16-9(a). Sixty days after service of the claim chart, Civil L.R. 16 — 9(b) requires the accused infringer to serve a detailed “response chart.” The response chart must disclose the identity of each item of prior art that anticipates the claim or renders it obvious, by its number, country of origin and [647]*647date of issue. Civil L.R. 16-9(b)(l). Each prior art publication must be identified by its title, date of publication, and where feasible, author and publisher. Civil L.R. 16-9(b)(l). The chart must also state whether a prior art (or combination of prior art) anticipates the claim or renders it obvious, where, specifically, within each item of prior art each claim element is found, and all other grounds of patent invalidity for any of the identified claims. Civil L.R. 16-9(b)(2)-(4).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
190 F.R.D. 644, 2000 WL 133749, Counsel Stack Legal Research, https://law.counselstack.com/opinion/amersham-pharmacia-biotech-inc-v-perkin-elmer-corp-cand-2000.